PDUFA V: FDA Offers Mid-Cycle Review Talks, But Industry Wants Them Later
Executive Summary
As negotiations about the next user fee cycle continue, FDA is offering an opportunity for sponsors to formally discuss an application's progress with reviewers, although it appears the new proposed meeting would come too early in the process for industry’s satisfaction.
You may also be interested in...
FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.
FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.
Biosimilars: FDA Casts Wide Net For Creation Of User Fees
Agency seeks "consultation meetings" with patient, consumer, professional and academic groups as it develops congressionally-mandated report on the nascent approval pathway.